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Abstract 
Sickle-cell disease is characterized by painful vaso-occlusive crises during which abnormal 
interactions between erythroid adhesion molecules and vessel-wall proteins are thought to play a 
critical role. Hydroxyurea, the only drug with proven benefit in sickle-cell disease, diminishes 
these interactions but its mechanism of action is not fully understood. We report that, under 
hydroxyurea, expression of the unique erythroid laminin receptor Lu/BCAM was increased but 
red blood cell adhesion to laminin decreased. Because Lu/BCAM phosphorylation is known to 
activate cell adhesion to laminin, it was evaluated and found to be dramatically lower in 
hydroxyurea-treated patients. Analysis of the protein kinase A pathway showed decreased 
intracellular levels of the upstream effector cAMP during hydroxyurea treatment. Using a cellular 
model expressing recombinant Lu/BCAM, we showed that hydroxyurea led to decreased 
intracellular cAMP levels and diminished Lu/BCAM phosphorylation and cell adhesion. We 
provide evidence that hydroxyurea could reduce abnormal sickle red blood cell adhesion to the 
vascular wall by regulating the activation state of adhesion molecules independently of their 
expression level. 
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Introduction 
Sickle-cell disease (SCD) is characterized by painful episodic vaso-occlusive crises (VOC), acute 
chest syndrome and a chronic inflammatory state. Hydroxyurea (HU), also called 
hydroxycarbamide, is the only drug now available having demonstrated benefit for SCD patients, 
with fewer VOC and acute chest syndromes, and lower mortality and morbidity.1-4 It was 
commonly thought that HU acted as an anti-sickling agent by increasing fetal hemoglobin (HbF) 
levels, leading to significantly less hemoglobin S polymerization. However, HU was often 
associated with clinical improvement before HbF rose significantly, suggesting that it could also 
act through other mechanisms.2 
Growing evidence supports the hypothesis that, in SCD patients, transit of red blood cells 
(RBCs) into small vessels could be slowed by their abnormal adhesion to the vascular wall 
through interactions between erythroid adhesion molecules and proteins on the surface of 
endothelial cells or extracellular matrix (ECM) components.5-7 Such interactions could play a 
critical role in HbS polymerization and VOC development by prolonging RBC transit time in 
capillaries. 
Several interactions have been described between SS RBCs and the endothelial vascular 
wall. Integrin α4β1, expressed on young circulating reticulocytes, is one of the major actors in 
these interactions through its binding to vascular cell-adhesion molecule-1 (VCAM-1), 
fibronectin, thrombospondin (TSP) and endothelial Lu/BCAM (Lutheran/basal cell-adhesion 
molecule).8-13 TSP mediates adhesion of SS reticulocytes to endothelial cells by bridging CD36 
molecules expressed on both cell types.14 However, the clinical severity of SCD in CD36-
deficient patients is not diminished.15 Landsteiner–Wiener/intercellular adhesion molecule-4 
(LW/ICAM-4) and Lu/BCAM are members of the immunoglobulin superfamily, expressed on 
young and mature RBCs; they are also involved in the abnormal adhesion of SS RBCs through 
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interactions with endothelial integrin αVβ3 and ECM laminin 511/521, respectively.16-21 In vivo, 
HU decreases the percentage of circulating CD36- and α4β1-expressing reticulocytes22 and CD36 
and α4β1 expression levels at the mRNA and protein levels;23 it also reduces phosphatidylserine 
expression on the surfaces of erythrocytes and platelets,24 and plasma levels of soluble VCAM-1 
and endothelin-1.25,26 HU diminishes SS RBC adhesion to endothelial cells and the ECM proteins, 
fibronectin, TSP and laminin.23,27,28 These decreases are consistent with less CD36, α4β1 and 
LW/ICAM-4 expression on the surfaces of SS reticulocytes and erythrocytes.29 
Surprisingly, Odièvre et al showed that RBC expression of Lu/BCAM, the unique 
erythroid receptor for laminin,19,21 was significantly elevated in HU-treated children.29 
Consequently, SS RBC adhesion to laminin could not be directly linked to the cell-surface 
Lu/BCAM expression level. Lu/BCAM is responsible for abnormal SS RBC adhesion to laminin 
in a protein-kinase A (PKA)- and/or Rap1-dependent manner.30,31 Although Lu/BCAM is 
expressed on normal (AA) and SS RBCs, only SS RBCs adhere to laminin and resist high shear-
stress forces.19,21,32 This adhesion is activated by the phosphorylation of serine 621 in the 
Lu/BCAM cytoplasmic domain upon PKA-pathway activation.33 Lu/BCAM is not 
phosphorylated in AA RBCs.33 
For this study, we hypothesized that HU could interfere with SS RBC adhesion to laminin 
by modulating Lu/BCAM phosphorylation. Adhesion to laminin of RBCs from adult SCD 
patients, HU-treated or not, was investigated during a quiescent phase of the disease (steady-
state). HU increased Lu/BCAM erythroid expression but decreased RBC adhesion to laminin; that 
diminished adhesion was correlated with less Lu/BCAM phosphorylation. Analysis of the 
signaling pathways involved in Lu/BCAM phosphorylation showed decreased intracellular levels 
of cAMP, the upstream effector of both PKA and Epac/Rap1 pathways, during HU treatment. 
These observations were then confirmed in a cellular model expressing recombinant Lu/BCAM 
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long isoform Lu. Our results provide the first evidence that HU could reduce abnormal RBC 
adhesion to the vascular wall by acting on the activation state of adhesion molecules, eg 
Lu/BCAM, independently of their expression level.
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Patients and Methods 
Patients and blood samples 
Homozygous SCD patients (SS) at least 18 years old, able to give their informed consent and 
consulting at our Adult Sickle-Cell Referral Center were eligible for inclusion in this study, which 
was approved by the local ethics committee (Comité de Protection des Personnes) and was 
conducted in accordance with the provisions of the Declaration of Helsinki, and local laws and 
regulations. Experiments were performed with freshly drawn EDTA-anticoagulated venous blood 
from healthy adult donors or HU-treated or untreated adult SS patients. SCD steady-state was 
defined as a visit at least ≥ 1 months after an acute clinical event and ≥ 3 months after blood 
transfusion. None of the included patients had an acute SCD-related event during the 2 weeks 
following sampling at steady-state. 
 
Cell lines and antibodies 
Human erythroleukemic K562 cells expressing the long human Lu/BCAM isoform (Lu gp), 
K562-Lu, were obtained and grown, in the absence or presence of 250 µM HU (Sigma-Aldrich, 
Saint-Quentin Fallavier, France) for 24 and 48 hours,27 as described.19 Mouse anti-human 
Lu/BCAM monoclonal antibody (mAb), clone F241, was produced in our institute.33 Biotinylated 
goat polyclonal anti-Lu/BCAM antibody was from R&D Systems (Minneapolis, MN). 
 
Flow cytometry 
Percentages of reticulocytes in whole or fractionated blood samples were determined using 
thiazole orange dye (Retic-CountTM, Becton-Dickinson, San Jose, CA) and a BD FACScanto II 
flow cytometer (Becton-Dickinson) with FACSDiva software (v6.1.2) for acquisition and 
analysis. The percentage was determined by gating the red cell population based on size (forward 
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scatter) and granularity (side scatter). Expression of cell-surface Lu/BCAM on RBCs and 
transfected K562-Lu cells was evaluated with anti-Lu/BCAM F241 mAb. Mean fluorescence 
intensity (MFI) was determined under the same conditions for all samples. Lu/BCAM antigen 
strength varies widely among individuals and exhibits heterogeneity between individual RBCs 
within a given individual. This variability accounts for the mixed field-agglutination patterns 
showing clumps of agglutinated cells in the presence of many free cells, usually seen with 
Lutheran antisera especially anti-Lua, and the wide range of survival times of Lu(b+) cells 
introduced into a Lu(a+b-) person with anti-Lub.34 Therefore, Lu/BCAM-positive RBCs were 
gated and Lu/BCAM MFI was calculated only for this population. 
 
Percoll double-density separation 
All collected blood samples designated for this fractionation were kept at 4°C overnight, then 
subjected to density separation at room temperature as described.35 Percoll (Sigma-Aldrich) was 
diluted in 125 mM NaCl, 4.5 mM KCl, 3% bovine serum albumin (BSA) to obtain densities of 
1.076 and 1.085; 3 ml of the latter density were placed in an empty 15-ml polypropylene tube 
followed by 3 ml of the former, then 3 ml of whole blood were carefully loaded onto the surface. 
After centrifugation (30 min, 1000×g), blood fractions were collected and washed 3 times with 
Hanks’ buffer (Sigma-Aldrich). An aliquot was saved to count reticulocytes by flow cytometry 
and the rest was used in adhesion and phosphorylation assays. 
 
Adhesion assays 
RBC and K562-Lu–cell adhesions to laminin were measured under physiological flow conditions 
using a plate flow chamber, by a person blinded to the patient’s status, as described.33 Laminin 
511/521 (10 µg, Sigma-Aldrich) from human placenta was immobilized in uncoated µI 
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microslides (ibidi, Munich, Germany) (internal channel dimensions: length 50 mm, width 5 mm, 
height 0.4 mm) at 4°C overnight. RBCs and K562-Lu cells were washed and suspended, 
respectively, in Hanks’ buffer supplemented with 0.2% BSA at hematocrit 0.5% and 107 cells/ml. 
Cells were perfused through the microslide at a shear stress of 0.4 dyne/cm2 for 5 min at 37°C and 
washouts used Hanks’ buffer at 0.4 and 2 dyne/cm2 for 5 min each. After each wash, adherent 
cells were counted in 5 representative areas along the centerline of the microslide by microscopy 
using Optimas 6.1 image analysis system (Media Cybernetics, Silver Spring, MD). 
 
Phosphorylation assays 
RBCs and K562-Lu cells were phospholabeled as described.33 Briefly, RBCs (200 µl) were 
incubated in 1.8 ml of buffer A (150 mM NaCl; 20 mM Tris-HCl, pH 7.5; 10 mM KCl; 1 mM 
MgCl2) for 4 hours at 35°C; centrifuged at 750×g for 3 min and suspended in 1.8 ml of buffer A 
containing 32P (300 µCi) for 14 hours at 35°C. RBCs were washed twice with cold PBS and lysed 
with buffer A containing 1% Triton X–100, 0.2% BSA, phosphatase (Sigma-Aldrich) and 
protease inhibitor cocktails (Roche, Basel, Switzerland). Lu/BCAM was immunoprecipitated with 
F241 mAb and protein A–Sepharose CL4B beads (Roche) overnight at 4°C. After SDS–PAGE 
and protein transfer, phosphorylated proteins were detected and quantified (P) with a FujiFilm 
BAS-1800 II PhosphorImager, using Image Reader BAS-1800 II V1.8 and Multi Gauge v3.0 
software, respectively (Fuji, Tokyo, Japan). Total Lu/BCAM was then revealed on the same 
membrane by Western blotting using biotinylated anti-Lu/BCAM antibody (R&D Systems) and 
the Molecular Imager Gel Doc XR System (Bio-Rad, Marnes-la-Coquette, France). Proteins were 
quantified (WB) using Quantity One software (Bio-Rad). The P/WB ratio was calculated to 
determine the proportion of phosphorylated Lu/BCAM among total immunoprecipitated 
Lu/BCAM proteins. 
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Cyclic AMP quantification 
Total cAMP was measured in RBCs and K562-Lu cells as described in the Cayman Chemical 
(Ann Arbor, MI) cAMP enzyme-immunoassay kit. Briefly, 70 µl of RBCs or 5×106 K562-Lu 
cells were lysed in 430 µl or 200 µl of 0.1 M HCl, respectively. After centrifugation, supernatants 
were acetylated and 50 µl of each were added per well in a 96-well ELISA plate provided in the 
kit. After an 18-hour incubation at 4°C, wells were washed and 200 µl of revelation buffer were 
added to each well. After 2 hours of incubation at room temperature, total cAMP levels were 
measured according to the manufacturer’s instructions. 
 
Statistical analyses 
Results are expressed as medians [interquartile range (IQR)], means ± SD, means ± s.e.m., 
numbers or percentages, as appropriate. Nonparametric tests were used because normal 
distribution could not be assumed because of the small samples (< 30) and those data had skewed 
distributions. Thus, quantitative parameters were compared between groups using a Mann–
Whitney test, Kruskal–Wallis test for > 2 groups, Wilcoxon signed-rank test for paired 
observations, or Friedman test for repeated measures. Fisher’s exact test was used for variance 
comparisons. Correlations were sought with simple linear regression and Pearson’s correlation. P 
≤ .05 was considered significant. 
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Results 
Patients 
The 49 homozygous SCD patients enrolled in this study formed 3 groups: 13 patients followed 
prospectively before and after starting HU (20 mg/kg/d), with 6 months of follow-up (pre–post 
group); 15 untreated patients (UT group); and 21 HU-treated patients (HU group). Results 
obtained with blood samples from the pre–post group before and > 6 months after starting HU 
were also included in the UT and HU groups, thereby raising the respective numbers of blood 
samples to 28 and 34. The mean ± SD age and the male/female ratio were 36 ± 8.34 years and 
0.75 for the UT group and 32 ± 8.64 years and 0.41 for the HU group. RBCs from 7 healthy 
donors were also analyzed. 
 
Less adhesion to laminin by SS RBCs from HU-treated patients 
The effect of HU treatment on SS RBC adhesion to laminin was investigated with adhesion assays 
under flow conditions with 34 blood samples from HU-treated patients and 28 from UT patients. 
HU-exposed SS RBCs adhered less than UT SS RBCs with respective medians of 40 vs 200 
RBCs/mm² at 2 dyne/cm² (P = .007) (Figure 1A) and 160 vs 550 RBCs/mm² at 0.4 dyne/cm² (P = 
.008) (not shown). The impact of HU on cell adhesion was also analyzed by comparing the UT 
and HU groups in terms of RBC-adhesion value distributions. We found that the dispersion of 
values was much wider for the UT group than the HU group, with significantly different between-
group variance values (Fisher’s exact test, P < .0001). Adhesion of RBCs from 7 control donors 
was close to null and significantly lower than for the UT and HU groups (P < .01). 
Because of wide interindividual variability in SCD, the same assays were run using blood 
samples from 13 pre–post group patients which showed that adhesion was significantly lower 
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after 6 months of HU (P = .013), and dramatically diminished for the 5 patients with the highest 
adhesion levels before starting HU (Figure 1B). 
 
SS RBC adhesion to laminin is not correlated with the Lu/BCAM expression level 
To determine whether SS RBC adhesion to laminin was conditioned by the Lu/BCAM expression 
level, flow cytometry and cell-adhesion assays were conducted with 14 and 12 HU- and UT-group 
blood samples, respectively. When all patients were taken into account, no correlation was found 
between the adhesion level and Lu/BCAM expression, as determined by the percentage of RBCs 
expressing Lu/BCAM or the number of Lu/BCAM molecules/RBC, estimated by Lu/BCAM-
positive RBC MFI (Figure 2A,B). When UT and HU-treated patients were considered separately, 
no correlation was found between adhesion level and Lu/BCAM expression, although a trend 
emerged for the UT group associating the adhesion level and MFI of Lu/BCAM-positive RBCs (P 
=.06, r2 = .3, n = 12). 
Paradoxically, and as previously reported by Odièvre et al,29 flow cytometry analysis of 
blood samples from 19 HU-group and 19 UT-group patients showed that the percentage of 
Lu/BCAM-expressing cells and the number of Lu/BCAM molecules/RBC were significantly 
higher for the HU group than the UT group (P < .0001) (Figure 2C,D); this result was also 
confirmed for 5 other pre–post group patients who had significantly increased Lu/BCAM 
expression under HU (Figure 2E,F). 
Two Lu/BCAM glycoprotein (gp) isoforms are present on human RBCs, Lu (85 kDa) and 
Lu(v13) (78 kDa); they result from the alternative splicing of intron 13 and differ by the lengths 
of their cytoplasmic domains.36,37 Because Lu/BCAM antigens reside on both isoforms, flow 
cytometry analysis could not show whether one or both of Lu/BCAM isoforms were 
overexpressed under HU. Therefore, Lu/BCAM gp were immunoprecipitated from SS RBCs of 5 
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pre–post group patients and revealed by Western blotting (Figure 3A, typical result). After protein 
quantification, the Lu/Lu(v13) ratio was determined for the 5 patients at all treatment stages 
(Figure 3B). It showed that Lu was predominantly expressed and that HU did not alter the 
Lu/Lu(v13) ratio. This finding indicated that Lu/BCAM overexpression under HU was due to an 
overexpression of both isoforms, suggesting that HU could up-regulate LU gene expression in 
erythroid cells. In addition, it showed that HU does not modulate the alternative splicing 
generating Lu and Lu(v13). 
 
Decreased Lu/BCAM phosphorylation on RBCs under HU 
We postulated that HU might reduce SS RBC adhesion by inhibiting Lu/BCAM activation. Lu, 
but not Lu(v13), is phosphorylated on SS RBCs in a PKA-dependent manner.33 To determine 
whether HU could modulate phosphorylation of the Lu isoform, radiophospholabeling 
experiments were performed with RBCs from the pre–post group to assess Lu phosphorylation 
status in the same individual before and during HU treatment. SS RBC samples were obtained 
from 5 patients before starting HU and at regular intervals during treatment: 15 days, 2, 4 and > 6 
months after starting HU. After RBC radiophospholabeling, Lu/BCAM was immunoprecipitated 
with F241 mAb, which recognizes the extracellular domain of both isoforms. Phosphorylated (P) 
Lu gp was quantified by phosphorImager after SDS–PAGE and protein transfer to a nitrocellulose 
membrane. Total amounts of immunoprecipitated Lu gp were then quantified on the same 
membrane by Western blotting (WB). The Lu-gp phosphorylated fraction was estimated by 
calculating the P/WB ratio of those determinations (Figure 4A, typical result). As expected, both 
isoforms were expressed on RBCs but only Lu gp was phosphorylated (Figure 4A). It is 
noteworthy that Lu phosphorylation decreased during HU treatment in this patient while no 
significant drop was observed for his percentage of circulating reticulocytes (Figure 4A). 
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Decreased Lu-gp phosphorylation was observed after 15 days of HU for 3 patients and within 2 
months for the 2 others. This reduction persisted throughout the 6 months of follow-up and was 
highly significant after 6 months of treatment (P = .005, n = 5 patients) (Figure 4B,C). Less 
phosphorylation was associated with reduced RBC adhesion to laminin (Figure 4D). A linear 
regression analysis showed a partial correlation between RBC adhesion and Lu/BCAM 
phosphorylation (Figure 4E, P = .0005, r² = 0.496). Three other parameters known to be 
modulated by HU were measured. As expected, the percentage of reticulocytes decreased during 
HU treatment (Figure 4F), while the Hb concentration and the percentage of HbF increased 
(Figure 4G,H). 
 
More adhesion to laminin of reticulocytes where Lu/BCAM phosphorylation mainly occurs 
The SCD RBC lifespan is dramatically shortened and the corresponding reticulocyte count is 
much higher than in healthy controls. To determine whether the SS reticulocyte percentage could 
influence RBC adhesion to laminin, flow-adhesion assays were performed with reticulocyte-
enriched UT RBCs obtained after whole blood fractionation by Percoll double-density gradient 
centrifugation. The median percentage of reticulocytes in whole blood (W), the low-density 
reticulocyte-rich fraction (LDF) and the pellet (reticulocyte-poor fraction, PF) were 8.2, 53 and 
4.8, respectively. The LDF exhibited the highest cell-adhesion level, adhering more than cells 
from whole blood (P < .01) and the pellet (P < .05) (Figure 5A). Because Lu/BCAM-mediated 
cell adhesion to laminin is modulated by phosphorylation, we analyzed Lu-isoform 
phosphorylation in both fractions and whole blood (Figure 5B). The phosphorylation level (P/WB 
ratio) was directly correlated to the percentage of reticulocytes (Figure 5C, P < .0001, r² = 0.985, 
n = 5 patients), indicating that Lu-gp was phosphorylated mainly in young immature RBCs of UT 
patients. 
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Considering these results we asked the question whether the decreased Lu/BCAM 
phosphorylation in HU-treated patients could be a consequence of the HU-driven decrease of 
circulating reticulocytes. To answer this question Lu/BCAM phosphorylation levels were 
determined in RBCs from 8 HU-treated patients and plotted against their percentage of 
reticulocytes (Figure 5D). As expected, low levels of Lu/BCAM phosphorylation were obtained 
for all patients. Interestingly, higher reticulocyte count was not associated with higher Lu/BCAM 
phosphorylation. Figure 5D shows that Lu/BCAM phosphorylation was independent of the 
reticulocyte percentage of HU-treated patients indicating that the decrease of Lu/BCAM 
phosphorylation in HU-treated patients was not a consequence of their decreased reticulocyte 
count. 
 
HU exposure leads to less K562-Lu cell adhesion to laminin and less Lu-gp phosphorylation 
In an attempt to test the effect of HU on SS RBCs in vitro, RBCs were incubated with or without 
HU for 24 and 48 hours at 37°C but, unfortunately, severe hemolysis ensued, even in the absence 
of HU. Therefore, SS RBCs were replaced by a transfected erythroleukemic cell line expressing 
recombinant Lu gp, K562-Lu cells. Adhesion and phospholabeling assays were run before and 
after incubating these cells with HU for 24 and 48 hours. Because HU is cytotoxic, cell viability 
was monitored by the cell-growth curve and flow cytometry using TO-PRO3 iodide. Cell 
proliferation was slowed down by HU and cell death was mildly but not sharply induced, as only 
2.4% and 4.7% dead cells were detected at 24 and 48 hours, respectively (n = 3). Adhesion at 24 
hours was comparable to untreated cells. K562-Lu cell adhesion to laminin was 12-fold lower at 
48 hours than untreated control cells (Figure 6A). This difference was not due to inhibition of Lu-
gp expression, as determined by flow cytometry (data not shown). The lower cell adhesion was 
associated with markedly less Lu-gp phosphorylation of HU-treated cells at 48 hours (Figure 6B), 
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confirming the relationship between the Lu-gp–phosphorylation level and cell adhesion, and 
showing that HU could diminish cell adhesion to laminin by modulating Lu-gp phosphorylation. 
 
Intracellular levels of cAMP are decreased under HU treatment 
Two signaling pathways involved in enhanced Lu/BCAM-mediated SS RBC adhesion to laminin 
have been described: the PKA30,33 and the Epac/Rap131 pathways. Because cAMP is a common 
upstream effector of both pathways, its intracellular levels were measured in SS RBCs. We first 
compared the basal levels of cAMP in SS versus AA RBCs and found higher levels in the former, 
as previously reported30 (Figure 7A). We then wondered whether cAMP production could be 
modulated under HU treatment. Intracellular levels of cAMP were determined in RBC samples of 
7 pre–post group patients and showed a steady and significant decrease over time (Figure 7B, P = 
.002). The effect of HU on intracellular cAMP levels was also measured using K562-Lu cells 
treated for 24 and 48 hours and yielded similar results (Figure 7C). These findings indicated that 
the lower Lu/BCAM phosphorylation under HU could be a direct consequence of a diminished 
stimulation of PKA and/or Epac/Rap1 pathways. 
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Discussion 
The pathophysiology of SCD is complex and not fully understood. The first step in the sickling 
process is HbS polymerization; hence, factors delaying reoxygenation of the HbS deoxygenated 
form or increasing the intracellular HbS concentration are thought to play major roles in initiating 
and accelerating the sickling process, consequently promoting the blockade of the 
microcirculation.38 RBC adhesion to the vascular wall probably favors the formation of HbS 
polymers by slowing the flow of cells circulating through capillaries, thereby leading to the next 
step, which is vaso-occlusion. Many observations support an important role of abnormal cell 
adhesion in the obstruction of microvessels or in facilitating the trapping of sickle cells in post-
capillary venules.5-7 We focused our study on Lu/BCAM, as they are the unique erythroid 
receptors of laminin, a major ECM protein, and are expressed in young and mature RBCs, unlike 
CD36 and integrin α4β1, which are restricted to reticulocytes. Considering the important 
interindividual heterogeneity in SCD and the variability of RBC characteristics during VOC,39 we 
applied strict patient inclusion criteria to minimize potential biases (see Patients and Methods). 
Hillery et al provided the first evidence that HU decreased SS RBC adhesion to TSP and 
laminin, but too few patients were studied to draw conclusions regarding potential correlations 
between RBC adhesion and the clinical response.28 Because HU modulates the expression of 
several genes, up-regulating HbF and down-regulating adhesion molecules CD36 and α4β1,22,23,29 
it could be expected that less adhesion to laminin resulted from less Lu/BCAM. Paradoxically, 
Odièvre et al’s findings did not support that hypothesis, as they showed that HU enhanced 
erythroid Lu/BCAM expression in children.29 Thus, SS RBC adhesion to laminin does not reflect 
the Lu/BCAM-expression level on the cell surface. 
Herein, we confirmed that HU significantly increased erythroid Lu/BCAM expression by 
enhancing both the percentage of Lu/BCAM-positive RBCs and the numbers of Lu/BCAM 
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copies/RBC. We showed that HU did not modulate the alternative splicing generating Lu and 
Lu(v13) isoforms but rather up-regulated erythroid expression of the LU gene. As expected, HU 
increased the Hb concentration and HbF percentage. Pertinently, the lower cell adhesion and 
Lu/BCAM phosphorylation preceded the HbF rise. Moreover, we showed that the reduced RBC 
adhesion to laminin under HU was associated with dramatically decreased Lu/BCAM long-
isoform phosphorylation, despite its enhanced expression, clearly demonstrated for the pre–post-
group patients. This decreased phosphorylation was most probably a direct consequence of the 
diminished intracellular cAMP levels measured in these patients during HU treatment. Thus, HU 
could modulate PKA and/or Epac/Rap1 pathways, downstream of cAMP, and inhibit Lu/BCAM 
phosphorylation. As intracellular cAMP levels are controlled by several effectors including 
adenylyl cyclase and phosphodiesterases, further studies are needed to fully characterize the HU 
mechanism of action in SCD. Our finding agrees with the results of other studies describing the 
role of HU in regulating cellular functions via signaling pathways. Some observations suggested 
that HU might raise nitric oxide levels by stimulating vascular endothelial cell production of it via 
the eNOS–cGMP pathway.40-43 HU could also prevent neutrophil activation and adhesion to 
fibronectin in a cAMP–PKA-dependent manner.44,45 The in vivo effect of HU on Lu/BCAM long-
isoform phosphorylation and cAMP decrease could not be tested ex vivo using SS RBCs because 
of hemolysis. Nevertheless, using human erythroleukemic K562-Lu cells expressing recombinant 
Lu gp, we showed that the ex vivo effects of HU were similar to those observed for SS RBCs from 
HU-treated SCD patients. Although the K562 cell line derives from an erythroid lineage it could 
not be compared to RBCs. Nevertheless, these experiments revealed that HU could negatively 
impact cAMP levels, Lu/BCAM phosphorylation and cell adhesion to laminin in this cell line 
suggesting that it could help deciphering the HU mechanism of action. 
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Another new finding was the correlation between Lu-gp phosphorylation and the 
percentage of reticulocytes in UT patients, which could explain why their reticulocyte-enriched 
fractions adhered more to laminin than mature RBCs. Two studies investigated SS RBC adhesion 
to laminin according to their density and reported that cells from the dense fraction were the most 
adherent.46,47 Our results were obtained using a different experimental approach to have 
reticulocyte-enriched fractions. The 5–10% of very dense and irreversibly sickled cells, reported 
to be the most adherent,46,47 were diluted in our pellet fraction with cells of intermediate density 
known to be much less adherent. We chose to focus on reticulocytes, because no Lu/BCAM 
phosphorylation was detected in mature dense RBCs and our objective was to determine the effect 
of HU on Lu/BCAM activation through the phosphorylation of the long Lu isoform. Our results 
showed that, contrary to what was observed for UT patients, the Lu/BCAM phosphorylation level 
was independent of the reticulocyte count in HU-treated patients, as patients with < 3% and > 7% 
of reticulocytes showed similar phosphorylation levels (Figure 5D). We showed that the HU 
effect on RBC adhesion preceded the reticulocyte count decline. Pre–post group RBC adhesion to 
laminin was often diminished before the reticulocyte count changed significantly, revealing a 
qualitative modification of the adhesive properties of circulating reticulocytes. This was clearly 
demonstrated for the patient in figure 4A who showed a dramatic decrease of Lu/BCAM 
phosphorylation after > 6 months of HU therapy while no significant change was observed for his 
percentage of circulating reticulocytes. In addition, the reticulocyte-count diminution under HU in 
the 5 pre–post group patients was not statistically significant (P = .26). Nevertheless, because the 
phosphorylation level results from the balance between kinase and phosphatase activities, and the 
RBC stock of kinases declines with age, it cannot be excluded that the prolongation of RBC 
survival under HU could partially contribute to the reduced Lu/BCAM phosphorylation. 
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In addition to phosphorylation, Lu/BCAM-mediated cell adhesion to laminin is regulated 
by the interaction of the Lu/BCAM cytoplasmic domain with the spectrin-based skeleton.48-50 
Loss of interaction with spectrin increases Lu/BCAM-mediated cell adhesion to laminin. 
48,49Since HbS polymerization during sickling generates skeleton disorganization, it could 
negatively affect the Lu/BCAM-spectrin interaction, of both Lu and Lu(v13) isoforms, and lead to 
enhanced adhesion of sickled RBCs, independently of phosphorylation events. This scenario 
could account for the partial correlation between phosphorylation and adhesion in our 
experiments (r² = 0.496) and for the previously reported high adhesion of very dense, irreversibly 
sickled cells.46,47 Several RBC skeletal proteins undergo phosphorylation, which regulates their 
interactions with other cytoplasmic proteins. Our results showed an HU impact on 
phosphorylation events in RBCs and, thus, it could modulate protein–protein interactions. Further 
studies are needed to investigate the role of the Lu/BCAM–spectrin interaction in SS RBC 
adhesion to laminin and the effect of HU on it. 
Altogether, our results strongly suggest a critical role for HU in inhibiting Lu-gp 
phosphorylation, which was associated with significantly less SS RBC adhesion to laminin. It is 
widely accepted that HU reduces SS RBC adhesion by down-regulating the reticulocyte count and 
the expression levels of adhesion molecules. Our findings show, for the first time, that HU could 
also play a role in reducing receptor–ligand interactions, most probably by modulating their 
affinity, which could explain the very short duration of HU pharmacological activity, independent 
of its reconditioned RBC renewal wave. 
 In conclusion, the results of our study reveal a new HU mechanism of action in regulating 
SS RBC adhesion by modulating the phosphorylation state of an adhesion molecule 
independently of its expression level. Future investigations should help characterize the pathway 
leading to this HU-induced modulation, which could give rise to new therapeutic perspectives.
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Figure Legends 
Figure 1. Fewer SS RBCs adhered to laminin during HU treatment. (A) Blood samples from 
7 healthy controls, 28 untreated (UT) and 34 HU-treated patients (HU). Horizontal lines are 
medians. UT RBCs were more adherent than HU RBCs (2 dyne/cm2, P = .007; Mann–Whitney 
test). Note that exposure to HU led to less dispersion of HU group values as compared to the UT 
group (P < .0001; Fisher’s exact test). (B) For the pre–post group, RBC adhesion was 
significantly lower after 6 months of HU (M6) than before (2 dyne/cm2, n = 13; P = .013; 
Wilcoxon signed-rank test). 
 
Figure 2. HU-exposed SS RBC adhesion to laminin decreased while Lu/BCAM erythroid 
expression increased. Lu/BCAM expression was measured by flow cytometry using anti-Lu 
monoclonal antibody F241. (A,B) SS RBC adhesion as a function of the percentage of RBCs from 
12 untreated (UT) and 14 HU-treated patients expressing Lu/BCAM (Lu/BCAM+) (A) or of 
Lu/BCAM mean fluorescence intensity (MFI) (B); (C,D) Lu/BCAM expression level on the 
surface of RBCs from 19 UT and 19 HU-treated patients represented as the percentage of 
circulating RBCs expressing Lu/BCAM (C) and the latter’s MFI (D); HU increased the 
percentage of Lu/BCAM-positive RBCs (P < .0001) and Lu/BCAM MFI (P < .0001; Mann–
Whitney test). Horizontal lines are medians. (E,F) Same as (C,D) for the 5 pre–post-group 
patients before (D0) and during HU treatment (D15, M2, M4 and >M6). 
 
Figure 3. Erythroid expression of Lu and Lu(v13) during HU treatment. Lu and Lu(v13) 
were immunoprecipitated and revealed by Western blotting. (A) Typical result showing the 
presence of Lu (85 kDa) and Lu(v13) (78 kDa) before and during HU treatment. (B) Box and 
whiskers representing the Lu/Lu(v13) ratio of 5 pre-post group patients during HU treatment. The 
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internal horizontal line is the median, lower and upper box limits correspond to the 25th and 75th 
percentiles and the T-bars represent the range. 
 
Figure 4. Lu/BCAM phosphorylation (P), RBC adhesion and evolution of 3 blood 
parameters during HU treatment. (A) Typical results (1 of 5 experiments) obtained with pre–
post-group patient’s SS RBCs showing the phosphorylation of the Lu-gp long isoform after RBC 
radiophospholabeling and immunoprecipitation of Lu/BCAM. The percentage of reticulocytes 
was determined by flow cytometry of each sample. Total immunoprecipitated Lu/BCAM proteins 
were quantified by Western blotting (WB). The P/WB ratio estimates the proportion of 
phosphorylated proteins. Vertical lines have been inserted to indicate repositioned gel lanes. (B) 
Box and whiskers representing Lu/BCAM phosphorylation in 5 patients before (D0) and during 
HU treatment (D15, M2 and >M6). The internal horizontal line is the median, lower and upper 
box limits correspond to the 25th and 75th percentiles and the T-bars represent the range. HU 
significantly decreased Lu/BCAM phosphorylation (P = .005; Friedman test) (AU: arbitrary 
units). (C) Lu/BCAM-phosphorylation change after 6 months of HU treatment for each of the 5 
patients. (D) Evolution of RBC adhesion under treatment for the 5 HU-treated patients. (E) A 
linear-regression analysis between RBC adhesion and Lu/BCAM phosphorylation (P = .0005, r² = 
0.496). (F, G, H) Box and whiskers representing the evolution of reticulocyte percentages, Hb 
concentrations and HbF percentages, respectively. 
 
Figure 5. RBC adhesion to laminin at 0.4 dyne/cm2 and Lu/BCAM phosphorylation (P) after 
blood fractionation. (A) Adhesion of UT RBCs from whole blood (W), the reticulocyte-rich low-
density fraction (LDF) and the pellet containing the mature RBC-rich fraction (PF). Horizontal 
lines are medians. More LDF cells adhered than those from W (P < .01) or the PF (P < .05; 
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Friedman test). (B) Typical results (1 of 5 experiments) showing the phosphorylation of the Lu-gp 
long isoform in W, LDF and PF of an UT patient. The percentage of reticulocytes was determined 
by flow cytometry for each sample. Total immunoprecipitated Lu/BCAM proteins were 
quantified by Western blotting (WB). P/WB ratio estimates the proportion of phosphorylated 
proteins. Vertical lines have been inserted to indicate repositioned gel lanes. (C) Linear regression 
between phosphorylation and reticulocyte percentage in UT-patients (r² = 0.985, P < .0001, n = 5 
patients, 3 samples for each patient: W, LDF and PF). (D) Lu/BCAM phosphorylation as a 
function of the reticulocyte percentage in 8 HU-treated patients (r² = 0.03, P = .66, n = 8). 
 
Figure 6. Adhesion of K562-Lu cells to laminin and Lu-gp phosphorylation (P) during 
exposure to HU. (A) Mean ± s.e.m. numbers of K562-Lu cells adhering to laminin at 2 dyne/cm2 
before (Control) and after 24 and 48 hours of exposure to 250 µM of HU (n = 3). (B) Lu-gp 
phosphorylation of HU-treated K562-Lu cells (typical result); means ± s.e.m. at 24 and 48 hours 
were 0.75 ± 0.27 and 0.27 ± 0.1, respectively (n = 3). HU exposure reduced K562-Lu adhesion to 
laminin and Lu-gp phosphorylation. 
 
Figure 7. Quantification of intracellular cAMP in RBCs and K562-Lu cells. Cyclic AMP 
levels were measured using an enzyme immunoassay. (A) cAMP levels in 4 AA and 7 SS RBC 
samples. Each dot represents the measured cAMP value in 108 RBCs from one patient. The 
horizontal lines are medians. (B) cAMP values measured in 7 patients during HU treatment at D0, 
D15, M2 and >M6. The decrease in cAMP levels was significant (P = .002; Friedman test). (C) 
Decreased cAMP values measured in K562-Lu cells incubated with HU for 24 and 48 hours. 
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